We are pleased to announce the appointment of two new partners and counsel!

On 5 December 2024 the results of the annual Pravo-300 law firms’ ranking were announced at an awarding ceremony at The Carlton Hotel in Moscow. This year Lidings expertise is highly praised in 17 key practice areas.

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.

We are delighted to announce that Lidings has updated The Pharma Legal Handbook: Russia - practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2024 the firm is ranked among the TOP leading legal advisors in Russia. 

Lidings is pleased to announce Natalya Thotahewage, a recognized expert in pharmaceuticals and healthcare, joining the firm as counsel and the appointment of Elizaveta Fursova, Head of the Lidings' Employment practice, as counsel.

On 7 December 2023 the results of the annual Pravo-300 law firms’ ranking were announced at an awarding ceremony at The Carlton Hotel in Moscow. This year Lidings expertise is highly praised in 15 key practice areas.

Lidings’ IP team has successfully secured recognition of the Doppelherz brand as a well-known trademark specifically for dietary supplements, setting a valuable precedent. The interests of the client, the German pharmaceutical company Queisser Pharma, which owns the brand, were represented by Boris Malakhov, Partner, and Vladislav Ryabov, Senior Associate.

Lidings Intellectual Property team has helped a major Russian manufacturer of pharmaceuticals, Pharmnovations, to achieve the annulment of the marketing authorization for a generic drug of a competitor company.